Research & Development


  • a unicorn chess piece sits on top of a stack of coins
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Where have all the unicorns gone? A look at 4 billion-dollar biotechs

    Not every unicorn company lives up to its $1 billion promise. Here are four worth watching.

    By Alexandra Pecci • Oct. 3, 2023
  • Puzzle of the human heart and doctor hand with the missing piece of puzzle
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The ALS therapy keeping the human pig heart transplant pumping

    Eledon’s investigational ALS drug tegoprubart could also help prevent organ transplant rejections, the company says.

    By Kelly Bilodeau • Oct. 2, 2023
  • clinical trial diversity Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • Jynneos Bavarian Nordic vaccine monkeypox
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip
    Q&A

    Inside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant

    Despite recent phase 3 setbacks in RSV and COVID-19, CEO Paul Chaplin sees a promising path forward in the travel vaccine market for the Danish biotech.

    By Sept. 27, 2023
  • AI human
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Do humans have a place in pharma’s AI future?

    From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.

    By Sept. 26, 2023
  • Growing plant in low poly wireframe style
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Why Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’

    The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.

    By Alexandra Pecci • Sept. 26, 2023
  • Old people silhouette
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Elderly exclusion: Clinical trials still fall short enrolling older adults

    Despite high rates of disease in older populations, systemic issues are keeping them out of research studies.

    By Kelly Bilodeau • Sept. 25, 2023
  • An open peanut shell sits on top a pile of other peanut shells.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Profile

    Three years after an FDA rejection, DBV sees a path for its peanut patch

    Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.

    By Sept. 22, 2023
  • PharmaVoice 100 header
    Image attribution tooltip
    Illustration: Deena So Oteh for Industry Dive/PharmaVoice
    Image attribution tooltip

    The 2023 PharmaVoice 100

    This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

    By Sept. 19, 2023
  • Horseshoe crab
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Endangered horseshoe crabs could lead the charge in pharma’s animal-free future

    An effort to spare the species from blood collection is one of many ways the industry is turning away from animals for R&D.

    By Kelly Bilodeau • Sept. 18, 2023
  • Pharma five-year plan
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

    Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.

    By Sept. 15, 2023
  • Close up of a machine with several tubes, some of which are red.
    Image attribution tooltip
    saengsuriya13 via Getty Images
    Image attribution tooltip
    Q&A

    In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.

    Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.

    By Sept. 14, 2023
  • leaders hands
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Catching up with 2022 PharmaVoice 100 honorees

    Tapping into our growing community for expertise and inspiration.

    By Sept. 13, 2023
  • highway
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Immuneering takes aim at cancer’s ‘superhighway’

    After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.

    By Kelly Bilodeau • Sept. 11, 2023
  • Professional headshot of Murray McKinnon
    Image attribution tooltip
    Courtesy of Empress Therapeutics
    Image attribution tooltip
    Profile

    Why this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery

    Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.

    By Alexandra Pecci • Sept. 6, 2023
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Hope sputters for emerging anti-TIGIT drug class

    Leaked data for Roche’s immunotherapy appeared positive, but some experts aren’t convinced it’ll make an impact for cancer patients.

    By Kelly Bilodeau • Sept. 5, 2023
  • Advarra 4 modernized functions header image.
    Image attribution tooltip
    Permission granted by Advarra
    Image attribution tooltip
    Sponsored by Advarra

    4 modernized functions every sponsor needs for study startup

    Explore four modern tech capabilities designed to help decrease cycle times, improve processes and compliance and mitigate site burdens.

    By Stuart Cotter, VP Product Innovation and Strategy, Advarra • Sept. 5, 2023
  • Mike Zappy Zapoline
    Image attribution tooltip
    Permission granted by Mike Zapolin
    Image attribution tooltip

    A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?

    Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

    By Sept. 1, 2023
  • Joe Biden stands at a podium flanked on either sides by screens that read: "lowering costs for American families."
    Image attribution tooltip
    Win McNamee / Staff via Getty Images
    Image attribution tooltip

    Medicare named the first 10 drugs up for negotiation. Now what?

    The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.

    By Aug. 30, 2023
  • Test tube blood
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    ‘We need to do better:’ A biotech CEO on standing apart from the crowd

    The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

    By Aug. 29, 2023
  • head brain pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Why pharma isn’t done tackling migraines

    In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options. 

    By Kelly Bilodeau • Aug. 28, 2023
  • COVID shot
    Image attribution tooltip
    Joe Raedle / Staff via Getty Images
    Image attribution tooltip

    ‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax

    New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.

    By Aug. 24, 2023
  • Henrietta Lacks
    Image attribution tooltip

    Steve Ruark/AP

    Image attribution tooltip

    Henrietta Lacks’ immortal cells put biopharma profits under a microscope

    The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.

    By Aug. 23, 2023
  • Brain scans are seen in a stock image
    Image attribution tooltip
    sudok1 via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Brii Biosciences aims to come up big where Sage and Biogen fell short

    The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.

    By Kelly Bilodeau • Aug. 21, 2023
  • Lonely sailing yacht in the ocean at the approaching storm and raining clouds at sunrise
    Image attribution tooltip
    Arsen Volkov via Getty Images
    Image attribution tooltip

    Behind Flagship Pioneering’s triumphs and tribulations

    From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.

    By Aug. 18, 2023
  • Shubh Goel, head of immuno-oncology, gastrointestinal tumors franchise, AstraZeneca
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip

    How an AstraZeneca exec is leading the charge in the next immuno-oncology era

    The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.

    By Aug. 17, 2023